DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* MAGNISENSE *


 

2003 - IDF
Rosny-sous-Bois (near Paris)
www.magnisense.com

 

Discovery, Diagnostics
Key words: Magnetic immunoassays, In-vitro diagnostics, Point-of-Care, Rapid tests, Super-paramagnetic particles, Magnetic detection, Portable reader, Cardiac markers, Infections, MIAtek, MIAstrip, MIAflo
Mission: to develop and market next-generation magnetic immunoassays that improve rapid diagnostic performance for human and animal diagnostics, food safety and environmental protection testing (immunoassays that are based on magnetic bead markers, which can be used to achieve the accuracy of laboratory testing with the ease of use of rapid test methods)
Clients: Diagnostic industry
info@magnisense.com

Age: 14 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Lenglet (Luc) [born 1964, Ph.D., Normale Sup (Paris), ex-Rhodia, Arthur D. Little]
Sc.Dir.-CSO: Nikitin (Petr) [Ph.D.]
Fin.Dir.-CFO:
RegMktg: El Yousfi (Hayat) [Mme, Pharm.D.]
BusDev: Péquignot (Clayton) [Ms. Biotechnology, ex-Cap Gemini Ernst and Young, Venstrata]
Financers (Hist.): Baring Vostok Capital Partners, Psilos Group, Seventure, Creadev (registered capital 2007 = 0.1 M€)
Note : legal foundation, February 20. 2007 (not 2003, as per company)

Turnover (M€) : 0.2 (2007)
Total funding (M€) : 7.0
Last funding (M€) : 1.0
Focus : Point of Care Testing
Position : Trade
Company confirm : none

 

History
DATEMILESTONETYPETIME
2011 .08 Round-financing : 1 M€, by existing shareholders, to support MIAtek technology platform development RFIN [8 years]
2011 .02 Legal move with Magnisense France as a dissolved company, replaced by Magnisense SE for R&D, and headquarters in Luxemburg ORGF [7 years]
2008 .10 Clinical trial positive, to view and characterize tissue lining the common bile duct at a microscopic level in real time with Cellvizio device, the world's smallest microscope CLIN [5 years]
2008 .04 Launch of MIAplex, a multiparametric magnetic technology MKTG [4 years]
2008 .03 Company expansion with new laboratories facility in Dardilly (near Lyon) ORGC [4 years]
2007 .04 Patent : filed for the invention of a new multiparametric magnetic immunoassay LEGAL [3 years]
2007 .02 Partnering development agreement with Indicia Biotechnology for joint testing platform of magnetic marker-based in vitro diagnostics R&D [3 years]
2006 .12 Nomination : Luc Lenglet, as CEO ORGN [3 years]
2006 .06 2nd round-financing : undisclosed M€, by Baring Vostok Capital Partners and private investors RFINB [3 years]
2006 .03 Patent : filed to protect special features of adapted lateral flow membrane cartridges LEGAL [2 years]
2003 .07 Patent : filed to protect a special embodiment of the technology LEGAL [0 year]
2003 .06 1st round-financing : undisclosed M€, by Baring Vostok Capital Partners and private investors RFINA [0 year]
2003 .05 Company founded by Baring Vostok Capital Partners and private investors, from technical development carried out jointly with the Russian Academy of Sciences in Moscow and Bertin technologies in France for engineering ORGF [0 year]

Actualisation / Updating: 28-Sep-2011

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende